Inside the research
Becton, Dickinson and Company
BDX Research profile · latest available data
Price overview
$183.82
▲ +4.59 (+2.6%)
| 52w hi | $190.87 |
|---|---|
| 52w lo | $135.29 |
| Vol | 1.47M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.22
| Short | +0.27 |
|---|---|
| Medium | +0.31 |
| Long | -0.06 |
computed 2026-09-27
Key fundamentals
Becton, Dickinson and Company
Healthcare · Medical Instruments & Supplies
| Market cap | $50.07B |
|---|---|
| Enterprise value | $66.17B |
| Trailing P/E | 31.86x |
| Forward P/E | 13.83x |
| EV / EBITDA | 10.81x |
| P / S (ttm) | 2.23x |
| Profit margin | 4.2% |
| Return on equity | 6.6% |
| Revenue growth | +5.4% |
| Earnings growth | -31.4% |
| Debt / equity | 68.84 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.08 | |
| Sector | +0.08 | |
| Technical | +0.19 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Risk Metrics
| Beta vs SPX | 0.46 |
|---|---|
| Corr SPX | 0.27 |
| Annual vol | 28.0% |
| Annual ret | +4.1% |
| Sharpe | 0.15 |
| Max DD | -33.7% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $183.29 |
|---|---|
| High / Low | $225.00 / $156.00 |
| Median | $176.00 |
| Analysts | 14 |
| Strong Buy | 1 | |
|---|---|---|
| Buy | 6 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-08 | Wells Fargo | → Equal-Weight |
| 2026-05-04 | TD Cowen | → Hold |
| 2026-04-17 | Piper Sandler | → Neutral |
| 2026-03-23 | Argus Research | → Buy |
| 2026-02-11 | Citigroup | → Buy |
| 2026-02-10 | Wells Fargo | → Equal-Weight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-06 | Earnings Release, Exhibits | read |
| 2026-07-22 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-05-29 | Reg FD Disclosure | read |
| 2026-05-20 | Material Agreement, Material Obligation… | read |
| 2026-05-12 | Other Material Event, Exhibits | read |
| 2026-05-07 | Earnings Release, Exhibits | read |
| 2026-04-29 | Bylaws Amendment, Exhibits | read |
| 2026-04-09 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-04-02 | Earnings Release, Exhibits | read |
| 2026-02-25 | Other Material Event, Exhibits | read |
| 2026-02-10 | Other Material Event, Exhibits | read |
| 2026-02-09 | Material Agreement, Officer / Director Change… | read |
Connections
Subsidiarys: BD Interventional
Dividends
| Yield (TTM) | 1.02% |
|---|---|
| $ / share (TTM) | $1.88 |
| 5y CAGR | +6.0% |
Annual dividend per share
| 2021 | $2.58 |
|---|---|
| 2022 | $2.75 |
| 2023 | $2.89 |
| 2024 | $3.06 |
| 2025 | $3.28 |
| 2026 | $1.05 |
Federal Contracts
| Amount | Agency | Description |
|---|---|---|
| $74.94M | Department of Veterans Affairs | COVID-19 TEST KITS |
| $33.79M | Department of Health and Human Services | BECTON DICKENSON: MULTIPLEXED RESPIRATORY PANEL TESTS FOR THE BD VERITOR, THE BD |
| $4.08M | Department of Health and Human Services | FACSYMPHONY A5 SE CELL ANALYZERS (8 CELL ANALYZERS) |
| $2.18M | Department of Veterans Affairs | BD REAGENTS AND SUPPLIES |
| $1.99M | Department of Health and Human Services | PURCHASE ORDER - BASE PERIOD - MAINTENANCE SERVICE CONTRACT FOR VARIOUS GOVERNME |
| $1.94M | Department of Veterans Affairs | FLOW CYTOMETRY |
| $1.42M | Department of Defense | A5SE BD FACSYMPHONY CELL ANALYZER |
| $1.27M | Department of Veterans Affairs | CTX MICROBIOLOGY AUTOMATION SYSTEM |
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $21.84B | +7.2% | |
| Gross profit | $1.66B | +9.7% | |
| Operating income | $2.40B | +2.8% | |
| Net income | $1.68B | +5.4% | |
| Cash from ops | $3.33B | +5.4% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $179.22 | $183.92 | $177.87 | $183.82 | 1.47M |
| Sep 24 | $182.73 | $183.72 | $178.98 | $179.23 | 1.40M |
| Sep 23 | $182.10 | $184.37 | $181.31 | $182.52 | 1.02M |
| Sep 22 | $182.40 | $183.83 | $180.75 | $183.00 | 1.46M |
| Sep 21 | $181.25 | $181.53 | $179.98 | $180.70 | 1.46M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →